Why RWD Strategy Can't Wait With Price, Value And Evidence Pressures Everywhere

By Ann-Louice Bruhn, RN, MSc, MBA, Adastra Partners LLC, and Ross Maclean, MD, Precision AQ

The pharmaceutical and biotech landscape is shifting under the weight of the Inflation Reduction Act (IRA), EU Joint Clinical Assessments (JCA), and evolving Medicaid pricing models. These regulatory hurdles have compressed revenue windows and heightened the demand for robust data that proves a drug's value beyond the controlled environment of a clinical trial. To navigate this, biopharmaceutical companies must transition from viewing Real-World Data (RWD) as a post-launch afterthought to a core, cross-functional strategy initiated as early as Phase I.

A proactive RWD strategy bridges the gap between clinical development and market access by identifying payer-relevant outcomes and contractable endpoints—such as hospitalization rates and treatment persistence—well before a product hits the market. Moving beyond functional silos allows every decision, from trial design to launch sequencing, to be grounded in the realities of patient experience and unmet need.